

## REVIEW

## Open Access

# The immunological and genetic aspects in psoriasis

Liangdan Sun<sup>1,2\*</sup> and Xuejun Zhang<sup>1,2</sup>\* Correspondence: [ahmusld@163.com](mailto:ahmusld@163.com)<sup>1</sup>Institute of Dermatology and Department of Dermatology at No.1 Hospital, Anhui Medical University, No. 81, Meishan Road, Hefei, Anhui 230032, China<sup>2</sup>Key Laboratory of Dermatology, Anhui Medical University, Ministry of Education, No. 81, Meishan Road, Hefei, Anhui 230032, China

## Abstract

Psoriasis is a chronic and immune-mediated inflammatory skin disorder associated with complex genetic susceptibility. Studies focused on the immunological mechanism have revealed innate and adaptive immune activation in psoriatic lesions, including large numbers of immune cells activated to produce many cytokines, chemokines, and other inflammatory molecules. Knowledge on the genetic basis of psoriasis highlights genetic susceptibility factors that play a crucial role in regulation of immunity, epidermal proliferation, and skin barrier formation. Genetic susceptibility factors affecting both the immune system and epidermis could predispose to disease. Herein, we review the current knowledge on the role of genetic and immunological factors in the development of psoriasis.

**Keywords:** Psoriasis; Immunity; Genetics; Pathogenesis

## Review

### Introduction

Psoriasis (MIM \*177900) is a common, chronic, and immunologically mediated inflammatory skin disease that affects individuals at rates varying from 0.5% to 4.6% across diverse ethnic populations (Lebwohl 2003). Symptoms typically develop in early adulthood, between the age of 15 and 25 years old (Henseler and Christophers 1985), but individuals of all ages can be affected. The disease has certain distinct but overlapping clinical phenotypes, including psoriasis vulgaris, which appears in approximately 90% of all patients (Griffiths and Barker 2007), and at least 10% to 30% of patients develop arthritis (Nickoloff and Nestle 2004; Ibrahim et al. 2009). Although psoriasis is rarely life threatening, its morbidity and associated comorbidities have a severe negative impact on the quality of life of the patients and also confer a certain socioeconomic burden. Over the past few decades, substantial researches on the pathogenesis of psoriasis have been a focus in the field of cutaneous disease. However, the mechanism of psoriasis pathogenesis likely involving the complex interplay among genetic, immunological, and environmental risk factors (Nestle et al. 2009) has not been fully elucidated.

The concordance of monozygotic twins both suffering from psoriasis has been reported to approximately 70%, and the sibling recurrence risk is estimated to range between 4 and 11 (Bhalerao and Bowcock 1998). Through a conventional family-associated on genetic linkage approach, psoriasis-associated chromosomal regions have been identified. A major genetic determinant of psoriasis, designated psoriasis susceptibility 1 (*PSORS1*), resides in

the major histocompatibility complex (MHC) on chromosome 6p21, tightly linked to *HLA-Cw6*, which is as the most frequently detected allele in psoriasis (Veal et al. 2002; Nair et al. 2006). More recently, with the development of high-throughput genotyping platforms and a comprehensive map of human haplotypes, genome-wide association studies (GWAS) have evolved into a powerful tool for investigating the genetic architecture of human complex diseases (Manolio et al. 2008). Taking advantage of GWAS, researchers have revealed many novel and/or confirmed previous genetic loci associated with disease, and ongoing studies are exploring additional genetic factors for associated with psoriasis.

The cellular features of psoriasis are epidermal hyperplasia and altered keratinocyte differentiation, but substantial evidence implicates both innate and acquired immunity in the disease pathogenesis (Gaspari 2006). The disease state is triggered by an activated cellular immune system, marked infiltration of T cells, dendritic cells (DCs), and inflammatory cytokines in psoriatic skin lesions (Bowcock and Krueger 2005). As in other immune-mediated diseases, such as rheumatoid arthritis (RA), Crohn's disease (CD), multiple sclerosis (MS), and juvenile-onset diabetes, psoriasis is regarded as a T cell-mediated autoimmune disease (Lowes et al. 2007). Therefore, it fits the definition of an autoimmune disease (Davidson and Diamond 2001). Recent progress in the understanding of both the immunological and genetic basis of the disease has provided a deep insight into the pathogenesis. In this review, we detail the recent advances in the understanding of psoriasis pathogenesis, including the information regarding immunological factors, genetic aspects, and susceptibility genes shared with other autoimmune or inflammatory diseases.

## **Immunological factors**

### ***Cells and molecules of immunity***

Psoriasis is characterized by hyper-proliferation and aberrant differentiation of keratinocytes (KCs), vascular abnormalities, and inflammatory infiltration. The cell types in psoriatic plaques are involved in wound repair and/or are composed of the antigen-presenting cells (APCs), including T lymphocytes cells, KCs, DCs, Langerhans cells (LCs), and macrophages. The cellular innate and adaptive immune responses, especially the activation of T cells, play a dominant pathogenic role in psoriasis (Krueger 2002; Cai et al. 2012). Evidence for the central role of T lymphocytes has been found in animal models of psoriasis (Boehncke and Schon 2007), successful treatment of psoriasis patients with cyclosporine A to inhibit T cell proliferation and cytokine production (Mueller and Herrmann 1979) and specifically recruited T cell clones that permanently involve the psoriatic inflammation (Vollmer et al. 2001). A dense infiltration is composed of clusters of CD4<sup>+</sup>T cells and antigen-presenting DCs in the dermis, while CD8<sup>+</sup>T cells and neutrophils are predominant in the epidermis of psoriatic lesions (Lowes et al. 2007). The expression of activation markers by both CD8<sup>+</sup>T and CD4<sup>+</sup>T cells has been observed in psoriatic lesions, and most of the T cells can also express the memory cell antigens (Liu et al. 2007). Once the psoriatic plaques appear after T cell infiltration as the activated memory-effector T cells, cytokines, such as interleukin (IL)-2, tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), and interferon  $\gamma$  (IFN- $\gamma$ ) could be generated, which stimulate an inflammatory response and change the characteristic of psoriasis (Austin et al. 1999; Friedrich et al. 2000). An interrelation exists in that, CD4<sup>+</sup>T cells may provide critical inductive and helper signals, while CD8<sup>+</sup>T cells are likely to be the

principal effector agents in the pathogenesis of psoriasis (Gudjonsson et al. 2004). Thus, in the epidermal compartment of psoriatic lesions, CD8<sup>+</sup>T cells could be activated and proliferated after CD4<sup>+</sup>T cells interact with antigen-presenting cells.

The changes in keratinocyte activation and proliferation that cause them to mature too rapidly result in psoriasis. Keratinocytes in psoriatic lesions produce an array of immune response-related proteins, such as the S100 proteins and intercellular adhesion molecule 1 (ICAM-1), CD40, and HLA-DR, which attract leukocytes. The link is that a positive feedback leads leukocytes to upregulate the S100 proteins (Bowcock and Krueger 2005). Upon activation, KCs express a plethora of cytokines, chemokines, and accessory molecules, transmitting both positive and negative signals to immune cells (Albanesi et al. 2005). KCs also produce endothelial cell mitogens such as VEGF and PDGF, leading to angiogenesis (Costa et al. 2007).

DCs are professional APCs involved in the regulation of the balance between immunity and immunological tolerance. Cytokine profile studies have shown that dermal DCs obtained from psoriatic lesions mediated a T cell response with high levels of IL-2 and IFN- $\gamma$  (Nestle et al. 1994). Plasmacytoid DCs (PDCs) have been identified in the psoriatic skin and in uninvolved, healthy-looking psoriatic skin and were shown to be the principal IFN- $\alpha$ -producing cells in early and developing psoriasis (Nestle et al. 2005). Myeloid DCs, which are activated by PDCs and keratinocyte-derived cytokines, are also accumulated in the psoriatic tissues (Zaba et al. 2009) and are believed to be required for sustaining and amplifying the T cell inflammatory reaction (Chu et al. 2011). Studies have shown that DCs may be the primary cell type that drives T-helper 17 (Th17) differentiation in psoriasis through the production of IL-6 and IL-23 (Chu et al. 2011). The crucial link between DCs and the IL-23/Th17 axis has been further strengthening the suggestion that DCs obtained from psoriatic lesions could activate T cells to produce both IL-17 and IFN- $\gamma$  (Zaba et al. 2009).

LCs reside in the basal and suprabasal layers of the skin and are closely associated and interact with KCs through E-cadherin (Tang et al. 1993). A role for LCs has been indicated in the pathogenesis of psoriasis (Cumberbatch et al. 2006), inducing the generation of distinct IL-22-producing Th22 cells infiltrating into the skin (Fujita et al. 2009). Macrophages can contribute to both epithelial-based and T cell-mediated pathways of inflammation in psoriasis (Clark and Kupper 2006). Macrophages interact with KCs and secrete a variety of pro-inflammatory cytokines, such as TNF- $\alpha$ , IFN- $\alpha/\beta$ , IL-1 $\beta$ , IL-6, IL-12, IL-10, and IL-18 cytokines, under various conditions (Wang et al. 2009a). Previous researches have suggested that the maintenance of psoriasiform skin inflammation critically depends on efficient recruitment and activation of macrophages with a sufficient release of TNF- $\alpha$  (Wang et al. 2006). As mentioned above, the cellular features of psoriasis are epidermal hyperplasia and altered keratinocyte differentiation, but mounting evidences have implicated both innate and acquired immunity in the disease progression of the disease (Nestle et al. 2009).

Several cytokines and chemokines, which induced keratinocyte proliferation, are strongly expressed in the psoriatic skin. It has been well established by many experimental studies that psoriatic inflammation mediated by T-helper 1 (Th1) cells (Uyemura et al. 1993; Schlaak et al. 1994). Characterization of cells and cytokines involved in the initiation and maintenance of psoriasis showed elevated levels of IFN- $\gamma$ , TNF- $\alpha$ , and IL-12, but not of IL-4, IL-5, or IL-10, at both the mRNA and protein levels (Nestle et al. 1994; Schlaak

et al. 1994; Austin et al. 1999). Th17 cells, a newly appreciated T cell subset that produce IL-17 (Miossec et al. 2009) and IL-22 (Liang et al. 2006), have been implicated in psoriasis. As a potent pro-inflammatory cytokine, IL-17 may stimulate keratinocytes to produce neutrophil-attracting CXC chemokines (Nogales et al. 2008), as well as CCL20, which draws CCR6<sup>+</sup> cells into sites of inflammation (Harper et al. 2009). A mixed Th1 and Th17 inflammatory environment is found in the affected skin during the disease process (Lowe et al. 2008). IL-23, which is composed of two subunits, a unique p19 subunit and a p40 subunit shared with IL-12 (Lee et al. 2004), represents a cytokine pathway that is differentially increased in psoriatic lesions and is important in Th17 cells. IL-23 is overproduced by DCs (Lee et al. 2004) and stimulates Th17 cells within the dermis to make cytokines in psoriatic lesions. Recent studies have demonstrated that the IL-23/Th17 cell axis plays an important role in the pathogenesis of psoriasis and presents a potential therapeutic target (Di Cesare et al. 2009; Nakajima 2012). In addition to IL-23 and IL-17, IL-22 has also been reported to induce cutaneous inflammation in an experimental murine model of psoriasis and has also been shown to induce *in vitro* an inflammatory-like phenotype *in vitro* (Van Belle et al. 2012). IL-22 is a member of the IL-10 cytokine family, which is primarily secreted by Th17 cells (Trifari et al. 2009). IL-22 is remarkably over-expressed in psoriasis, most likely as a result of upregulated the levels of IL-23 and IL-6 (Boniface et al. 2007; Zheng et al. 2007). TNF- $\alpha$  has been identified as a promising target molecule, with the expression of TNF- $\alpha$  and its receptors enhanced in psoriasis (Ettehadi et al. 1994). The efficacy of TNF- $\alpha$  antagonists in the treatment of psoriasis suggests a central role of this factor in psoriatic plaque formation (Tobin and Kirby 2005).

In addition to T cell-derived cytokines, numerous antigen-presenting cells infiltrate the psoriatic skin and produce inflammatory cytokines. A variety of chemokines and chemokine receptors are present in psoriatic plaques. The percentages of peripheral blood CD8<sup>+</sup>T cells expressing CXCR6 are higher in psoriasis patients than in healthy individuals, and CXCL16-CXCR6 interactions mediate the homing of CD8<sup>+</sup>T cells to psoriatic lesion (Gunther et al. 2012). In immune-pathogenesis of psoriasis, including TARC (CCL17), MIG (CXCL9), IP10 (CXCL10), MDC (CCL22), and RANTES (CCL5), as well as CXCR2, CXCR3, CCR4, CCL27-CCR10, MIP3 $\alpha$  (CCL20), MIP3 $\beta$  (CCL19), and CCR6, all involved in the inflammatory response of psoriasis (Nickoloff and Nestle 2004). Once chemokines bind to their respective receptors, they activate the cells to release of cytokines and growth factors to form a thick, erythematous scaly plaque.

### Inflammation pathways

Psoriasis is a representative inflammatory skin disease, which is mediated through a cytokine network. The activated DCs and T cells are central in its pathogenesis, creating a Type 1 inflammatory pathway, which links the activation of multiple inflammatory responses, such as the release of IFN- $\gamma$ , IL-23, and IL-12 into the lesions (Lew et al. 2004). This model is conceptually useful, but it accounts for only a small fraction of the pathogenesis and cannot explain the total inflammatory character of psoriatic lesions.

Previous studies have shown that the activity of the p38 mitogen-activated protein kinases (MAPKs) is increased in the psoriatic skin, supporting the potential role of these kinases in the pathogenesis of psoriasis (Funding et al. 2007). The mitogen- and stress- activated protein kinases 1(MSK1) are found to be involved in the phosphorylation of cyclic adenosine monophosphate response element-binding (CREB) protein in

keratinocytes and regulate the expression of the pro-inflammatory cytokines IL-6, IL-8, and TNF- $\alpha$  (Funding et al. 2006). Evidence shows that MAPK inhibitors are effective anti-inflammatory drugs that reduce the synthesis of inflammation mediators at multiple levels and block pro-inflammatory cytokine signaling (Kaminska and Swiatek-Machado 2008). It has therefore been confirmed that the pathway of the p38 MAPK/MSK1 signaling pathway may play a potential role in psoriasis by producing pro-inflammatory cytokines (Arthur and Darragh 2006).

Clearly, transcription factors, such as signal transducer and activator of transcription 1 and 3 (STAT1 and STAT3) and nuclear factor- $\kappa$ B (NF- $\kappa$ B), are activated in psoriasis. Research on the transcriptional regulatory network for psoriasis shows that E2F transcription factor 1 (E2F1), jun proto-oncogene (JUN), NF- $\kappa$ B 1, STAT1, STAT3, and SP3 are pivotal in the transcriptome network involved in the mechanism of psoriasis (Lu et al. 2013). NF- $\kappa$ B is a key regulatory element in inflammatory pathways, in cellular proliferation and differentiation, and in apoptosis as well as a crucial mediator in psoriasis (Goldminz et al. 2013). In a mouse model of psoriasis, NF- $\kappa$ B signaling is essential for the pathogenesis and is strongly activated in psoriatic lesions (Wang et al. 2009b). Compared to the non-psoriatic skin, the samples of the psoriatic skin demonstrate elevated levels of activated, phosphorylated NF- $\kappa$ B (Lizzul et al. 2005). It is targeted by numerous effector cells, including keratinocytes, Th17, and DCs, which respond to extracellular stimuli consisting of TNF- $\alpha$ , plasmin, and TLRs (Goldminz et al. 2013). A blockade of NF- $\kappa$ B signaling within various target cells leads to decrease production of pro-inflammatory cytokines.

The Janus kinase (JAK)/STAT signaling pathway is well known to be involved in many cellular processes including inflammation. The JAK/STAT pathway converts cytokine signals into genomic responses that regulate proliferation and differentiation of the immune cells (Kaminska and Swiatek-Machado 2008). JAK inhibitors may be a new class of immunomodulatory agents with immunosuppressive, anti-inflammatory, and antiallergic properties. When keratinocytes from the psoriatic skin were cultured, a significant induction of the STAT1-induced transcriptional activity was stimulated with either IFN- $\gamma$  or IFN- $\alpha$  (Hald et al. 2013). STAT3 are involved in the upregulation of keratin 17 (K17) expression induced by IL-22. Both STAT1 and STAT3 pathways are involved in the upregulation of K17 expression induced by IL-17A, and this regulation could be partially suppressed by STAT1 or STAT3 small interfering RNAs and inhibitors (Shi et al. 2011). Taken together, these cellular signaling pathways, which have been shown to be involved in the progression of psoriasis, present potential targets for new psoriasis therapies.

## **Genetic factors**

### ***Linkage and candidate gene association study***

Although psoriasis has a multifactorial etiology, it is strongly influenced by genetic factors (Lowes et al. 2007). Compared with the general population, a higher incidence of the disease has been identified among first-degree and second-degree relatives of psoriasis. The risk of psoriasis is greater in monozygotic twins than in dizygotic twins, confirming the genetic basis of the disease (Nestle et al. 2009). Prior traditional approaches, such as family-based linkage studies and population-based candidate gene association studies, have had some success in identifying genetic risk factors. The major



locus strongly associated with psoriasis is *PSORS1* on chromosome 6p21, spanning approximately 300 kb of the MHC class I region (Veal et al. 2002). Large-scale resequencing has established *HLA-C* and its *HLA-Cw\*06* allele as the most likely *PSORS1* candidate genes (Nair et al. 2006). Variants associated with the *HLA-Cw\*06* allele contribute to one-third and one-half of the genetic susceptibility to psoriasis (Elder 2006) and are determinant for the development of early-onset psoriasis (Zhang et al. 2003).

In addition to *PSORS1*, linkage analyses and association studies have highlighted psoriasis loci on several other chromosomes outside of the MHC region, designated *PSORS2-PSORS10* (Bowcock and Krueger 2005; Perera et al. 2012). *PSORS2* was localized to the chromosomal region 17q25.3 in a family of European ancestry and has also been observed in a Taiwanese family with multiple psoriasis-affected members (Jordan et al. 2012). Two disease-causing *CARD14* mutations in psoriasis identified by using genomic capture and DNA sequencing suggest that the involvement of *PSORS2* is due to the mutation of this gene (Jordan et al. 2012). In the *PSORS3* locus, on chromosome 4q (Matthews et al. 1996), evidence from an association study suggests a putative association between the interferon regulatory factor 2 (*IRF2*) and psoriasis, which indicates that the *IRF2* gene as a candidate for *PSORS3* (Foerster et al. 2004). *PSORS4* is in the 1q21 region (Matthews et al. 1996), where a common deletion (*LCE3C\_LCE3B-del*) in the late cornified envelope (LCE) cluster is associated with psoriasis (Coto et al. 2011). The locus, *PSORS5*, on chromosome 3q21 has been found in family-based analysis studies (Enlund et al. 1999). The cystatin A, zinc finger protein 148, and solute carrier family 12 member A8 (*SLC12A8*) genes are proposed as candidate genes at the psoriasis susceptibility locus *PSORS5* (Samuelsson et al. 2004; Huffmeier et al. 2005). *PSORS6*, located at 19p13 (Lee et al. 2000), has been suggested to interact with *PSORS1* (Huffmeier et al. 2009). *PSORS7* at 1p (Veal et al. 2001), *PSORS8* at 16q (Nair et al. 1997), and *PSORS9* at 4q31-34 (Yan et al. 2007; Zhang et al. 2007) are all linked to psoriasis. Although other susceptibility loci and genes have also been postulated, it is difficult to replicate the results of these studies, a result of interethnic differences and environmental variations.

### Genome-wide association studies

GWAS have become an effective approach for identifying genetic variants associated with disease risk (Price et al. 2010). To date, several large GWAS for psoriasis in both the European and Asian populations have been performed (Nair et al. 2009; Zhang et al. 2009; Ellinghaus et al. 2010; Huffmeier et al. 2010; Strange et al. 2010; Stuart et al. 2010; Sun et al. 2010; Tsoi et al. 2012) to identify novel susceptibility genes and mechanisms associated with psoriasis with kinds of algorithms (Tables 1 and 2). It is worth mentioning that the most highly significant associated single nucleotide polymorphisms (SNPs) in different populations are localized in the MHC class I region, which encodes the HLA molecules *HLA-A*, *HLA-B*, and *HLA-C*. The findings of GWAS pertaining to psoriasis and psoriatic arthritis GWAS (Liu et al. 2008) demonstrate that the strongest associated SNP alleles are highly correlated with the *HLA-Cw\*06*, which is consistent with the previously described involvement of the *PSORS1* region. Through in-depth analyses of the GWAS data, two additional susceptibility loci within the HLA region have been shown to confer risk of psoriasis in both Chinese and European lineages (Feng et al. 2009).

**Table 1 The genetic loci associated with psoriasis identified by GWAS**

Chromosomal	Reported gene(s)	SNP	Context	P value	Odds ratio (95% CI)	Population	Ref.
1q21.3	<i>LCE3B, LCE3D</i>	rs6677595	Intergenic	$2.1 \times 10^{-33}$	1.26 [NR]	European	(Tsoi et al. 2012)
	<i>LCE3D, LCE3A</i>	rs4085613	Intergenic	$7 \times 10^{-30}$	1.32 [1.25 to 1.39]	Chinese	(Zhang et al. 2009)
	<i>LCE3D</i>	rs4112788	Intergenic	$3 \times 10^{-10}$	1.29 [1.19 to 1.40]	European	(Strange et al. 2010)
1p36.23	<i>SLC45A1, TNFRSF9</i>	rs11121129	Intergenic	$1.7 \times 10^{-8}$	1.13 [NR]	European	(Tsoi et al. 2012)
1p36.11	<i>RUNX3</i>	rs7536201	nearGene-5	$2.3 \times 10^{-12}$	1.13 [NR]	European	
	<i>IL28RA</i>	rs7552167	Intergenic	$8.5 \times 10^{-12}$	1.21 [NR]	European	
		rs4649203	Intergenic	$7 \times 10^{-8}$	1.13 [1.05 to 1.22]	European	(Strange et al. 2010)
1p31.3	<i>IL23R</i>			$3.91 \times 10^{-12}$	1.16 [NR]	Chinese	(Cheng et al. 2013)
		rs2201841	Intron	$1.75 \times 10^{-10}$	1.23 [NR]	European	(Elder 2009)
		rs9988642	nearGene-3	$1.1 \times 10^{-26}$	1.52 [NR]	European	(Tsoi et al. 2012)
		rs11209026	Missense	$7 \times 10^{-7}$	1.49 [1.27 to 1.74]	European	(Strange et al. 2010)
		rs2201841	Intron	$3 \times 10^{-8}$	1.13 [NR]	European	(Nair et al. 2009)
2q24.3	<i>IFIH1</i>	rs17716942	Intron	$1 \times 10^{-13}$	1.29 [1.17 to 1.43]	European	(Strange et al. 2010)
2p16.1	<i>FLJ16341, REL</i>	rs62149416	Intergenic	$1.8 \times 10^{-17}$	1.17 [NR]	European	(Tsoi et al. 2012)
	<i>REL</i>	rs702873	Intron	$4 \times 10^{-9}$	1.12 [1.04 to 1.20]	European	(Strange et al. 2010)
	<i>NR</i>	rs842636	Intron	$6 \times 10^{-6}$	1.15 [NR]	European	(Stuart et al. 2010)
2p15	<i>B3GNT2</i>	rs10865331	Intergenic	$4.7 \times 10^{-10}$	1.12 [NR]	European	(Tsoi et al. 2012)
5q33.3	<i>PTTG1</i>	rs2431697	Intergenic	$1.11 \times 10^{-8}$	1.20 [1.13 to 1.28]	Chinese	(Sun et al. 2010)
	<i>IL12B</i>	rs12188300	Intergenic	$3.2 \times 10^{-53}$	1.58 [NR]	European	(Tsoi et al. 2012)
		rs2546890	ncRNA	$1 \times 10^{-20}$	1.54 [1.32 to 1.79]	European	(Ellinghaus et al. 2010)
		rs3213094	Intron	$5 \times 10^{-11}$	1.39 [1.26 to 1.53]	European	(Strange et al. 2010)
		rs2082412	Intergenic	$2 \times 10^{-28}$	1.44 [NR]	European	(Nair et al. 2009)
		rs3213094	Intron	$3 \times 10^{-26}$	1.28 [1.23 to 1.35]	Chinese	(Zhang et al. 2009)
		rs2082412	Intergenic	$4.75 \times 10^{-18}$	1.42 [NR]	European	(Elder 2009)

**Table 1 The genetic loci associated with psoriasis identified by GWAS (Continued)**

5q33.1	<i>TNIP1/ANXA6</i>	rs3762999	Intergenic	$4.55 \times 10^{-18}$	1.23 [1.18 to 1.29]	Chinese	(Sun et al. 2010)
		rs999556	Intergenic	$3.83 \times 10^{-21}$	1.25 [1.20 to 1.31]	Chinese	
	<i>TNIP1</i>	rs17728338	Intergenic	$1.4 \times 10^{-13}$	1.56 [NR]	European	(Elder 2009)
		rs2233278	UTR-5	$2.2 \times 10^{-42}$	1.59 [NR]	European	(Tsoi et al. 2012)
		rs17728338	Intergenic	$1 \times 10^{-20}$	1.59 [NR]	European	(Nair et al. 2009)
5q15	<i>IL13, IL4</i>	rs1295685	Intergenic	$3.4 \times 10^{-10}$	1.18 [NR]	European	(Tsoi et al. 2012)
	<i>IL13</i>	rs20541	Missense	$5 \times 10^{-15}$	1.27 [NR]	European	(Nair et al. 2009)
	<i>ERAP1</i>	rs27432	Intron	$1.9 \times 10^{-20}$	1.2 [NR]	European	(Tsoi et al. 2012)
		rs27524	Intron	$3 \times 10^{-11}$	1.13 [1.05 to 1.22]	European	(Strange et al. 2010)
		rs151823	Intergenic	$9.32 \times 10^{-9}$	0.89 [0.85 to 0.92]	Chinese	(Sun et al. 2010)
5q15	<i>LNPEP</i>	rs2303138	Missense	$1.83 \times 10^{-13}$	1.16 [NR]	Chinese	(Cheng et al. 2013)
6q25.4	<i>EXOC2, IRF4</i>	rs9504361	Intergenic	$2.1 \times 10^{-11}$	1.12 [NR]	European	(Tsoi et al. 2012)
6q25.3	<i>TAGAP</i>	rs2451258	Intergenic	$3.4 \times 10^{-8}$	1.12 [NR]	European	
6q23.3	<i>TNFAIP3</i>	rs610604	Intron	$3.07 \times 10^{-10}$	1.23 [NR]	European	(Elder 2009)
		rs582757	Intron	$2.2 \times 10^{-25}$	1.23 [NR]	European	(Tsoi et al. 2012)
		rs610604	Intron	$9 \times 10^{-12}$	1.19 [NR]	European	(Nair et al. 2009)
		rs33980500	Missense	$4.2 \times 10^{-45}$	1.52 [NR]	European	(Tsoi et al. 2012)
6q21	<i>TRAF3IP2</i>	rs458017	Missense	$2 \times 10^{-16}$	1.37 [1.22 to 1.54]	European	(Strange et al. 2010)
		rs13196377	Intron	$1.39 \times 10^{-12}$	1.67 [1.45 to 1.93]	European	(Huffmeier et al. 2010)
		rs13190932	Intron	$8.56 \times 10^{-17}$	1.83 [1.59 to 2.12]	European	
		rs13210247	Missense	$1.73 \times 10^{-14}$	1.69 [1.48 to 1.94]	European	
		rs33980500	Missense	$1 \times 10^{-16}$	NR	European	(Ellinghaus et al. 2010)
		rs240993	Intron	$5 \times 10^{-20}$	1.25 [1.16 to 1.34]	European	(Strange et al. 2010)
		rs1265181	Intergenic	$1.93 \times 10^{-208}$	22.62 [NR]	Chinese	(Zhang et al. 2009)
6p21.33	<i>HLA-C</i>	rs12191877	Intergenic	$2.98 \times 10^{-178}$	2.87 [NR]	European	(Elder 2009)



**Table 1 The genetic loci associated with psoriasis identified by GWAS (Continued)**

		rs13191343	Intergenic	$2.32 \times 10^{-72}$	2.37 [2.16 to 2.61]	European	(Huffmeier et al. 2010)
		rs12191877	Intergenic	$4 \times 10^{-32}$	2.79 [2.35 to 3.33]	European	(Ellinghaus et al. 2010)
		rs10484554	Intergenic	$4 \times 10^{-214}$	4.66 [4.23 to 5.13]	European	(Strange et al. 2010)
		rs12191877	Intergenic	$1 \times 10^{-100}$	2.64 [NR]	European	(Nair et al. 2009)
		rs10484554	Intergenic	$2 \times 10^{-39}$	2.8 [2.40 to 3.30]	European	(Liu et al. 2008)
		rs3134792	Intergenic	$1 \times 10^{-9}$	NR	European	(Capon et al. 2008)
	HLA-B, HLA-C	rs4406273	Intergenic	$4.5 \times 10^{-723}$	4.32 [NR]	European	(Tsoi et al. 2012)
	HCP5	rs2395029	ncRNA	$2 \times 10^{-26}$	4.1 [3.10 to 5.30]	European	(Liu et al. 2008)
7p14.1	ELMO1	rs2700987	Intron	$4.3 \times 10^{-9}$	1.11 [NR]	European	(Tsoi et al. 2012)
8p23.2	CSMD1	rs7007032	Intron	$3.78 \times 10^{-8}$	1.16 [1.10 to 1.22]	Chinese	(Sun et al. 2010)
		rs10088247	Intron	$4.54 \times 10^{-9}$	1.17 [1.11 to 1.23]	Chinese	
9q34.13	TSC1	rs1076160	Intron	$6 \times 10^{-6}$	1.09 [NR]	European	(Nair et al. 2009)
9q31.2	KLF4	rs10979182	Intergenic	$2.3 \times 10^{-8}$	1.12 [NR]	European	(Tsoi et al. 2012)
9p21.1	DDX58	rs11795343	Intron	$8.4 \times 10^{-11}$	1.11 [NR]	European	
10q22.3	ZMIZ1	rs1250546	Intron	$6.8 \times 10^{-7}$	1.1 [NR]	European	
11q24.3	ETS1	rs3802826	Intron	$9.5 \times 10^{-10}$	1.12 [NR]	European	
	ZC3H12C	rs4561177	nearGene-5	$7.7 \times 10^{-13}$	1.14 [NR]	European	
11q13.1	RPS6KA4, PRDX5	rs645078	Intergenic	$2.2 \times 10^{-6}$	1.09 [NR]	European	
12q13.3	STAT2, IL23A	rs2066819	Intergenic	$5.4 \times 10^{-17}$	1.39 [NR]	European	
	IL23A, STAT2	rs2066808	Intron	$1 \times 10^{-9}$	1.34 [NR]	European	(Nair et al. 2009)
	IL23A	rs2066807	Missense	$1.9 \times 10^{-5}$	1.33 [NR]	European	(Elder 2009)
		rs2066808	Intron	$2 \times 10^{-7}$	1.49 [1.28 to 1.73]	European	(Strange et al. 2010)
12q13.2	RPS26	rs12580100	Intergenic	$1 \times 10^{-6}$	1.17 [NR]	European	(Stuart et al. 2010)
13q14.11	COG6	rs7993214	Intron	$2 \times 10^{-6}$	1.41 [1.22 to 1.61]	European	(Liu et al. 2008)
	GJB2	rs3751385	UTR-3	$8.57 \times 10^{-8}$	0.87 [0.84 to 0.91]	Chinese	(Sun et al. 2010)

**Table 1 The genetic loci associated with psoriasis identified by GWAS (Continued)**

14q13.2	<i>NFKB1A, PSMA6</i>	rs12586317	Intron	$2.7 \times 10^{-8}$	1.15 [NR]	European	(Stuart et al. 2010)
	<i>NFKB1A</i>	rs8016947	Intergenic	$2.7 \times 10^{-11}$	1.19 [1.11 to 1.27]	European	(Strange et al. 2010)
16p13.13	<i>PRM3, SOCS1</i>	rs367569	Intergenic	$3.9 \times 10^{-10}$	1.12 [NR]	Chinese	(Li et al. 2013)
	<i>PRSS53, FBXL19</i>	rs12445568	Intergenic	$4.9 \times 10^{-8}$	1.13 [NR]	European	(Tsoi et al. 2012)
16p11.2	<i>FBXL19, POL3S</i>	rs10782001	Intron	$1.2 \times 10^{-16}$	1.16 [NR]	European	(Stuart et al. 2010)
	<i>CARD14</i>	rs11652075	Missense	$9.7 \times 10^{-10}$	1.16 [NR]	European	(Stuart et al. 2010)
17q25.3	<i>PTRF, STAT3, STAT5A/B</i>	rs963986	Intergenic	$3.4 \times 10^{-8}$	1.11 [NR]	European	(Tsoi et al. 2012)
17q11.2	<i>NOS2</i>	rs28998802	Intron	$5.3 \times 10^{-9}$	1.15 [NR]	European	(Tsoi et al. 2012)
		rs4795067	Intron	$3.3 \times 10^{-16}$	1.22 [NR]	European	(Stuart et al. 2010)
18q22.1	<i>NR</i>	rs1975974	Intergenic	$4.7 \times 10^{-11}$	1.19 [NR]	European	(Stuart et al. 2010)
	<i>SERPINB8</i>	rs514315	nearGene-3	$1.7 \times 10^{-7}$	1.17 [NR]	European	(Stuart et al. 2010)
18q21.2	<i>POL1, STARD6, MBD2</i>	rs545979	Intergenic	$5.92 \times 10^{-9}$	0.87 [0.83 to 0.91]	Chinese	(Sun et al. 2010)
19q13.41	<i>ZNF816A</i>	rs9304742	Intron	$3.5 \times 10^{-10}$	1.12 [NR]	European	(Tsoi et al. 2012)
19p13.2	<i>ILF3, CARM1</i>	rs892085	Intergenic	$2.11 \times 10^{-9}$	0.88 [0.84 to 0.92]	Chinese	(Sun et al. 2010)
	<i>TYK2</i>	rs34536443	Missense	$3.0 \times 10^{-17}$	1.17 [NR]	European	(Tsoi et al. 2012)
20q13.13		rs12720356	Missense	$9.1 \times 10^{-31}$	1.88 [NR]	European	(Strange et al. 2010)
		rs280519	Intron	$4.7 \times 10^{-11}$	1.4 [1.23 to 1.61]	European	(Strange et al. 2010)
20q13.12	<i>ZNF313</i>	rs2235617	Intron	$4.7 \times 10^{-9}$	1.13 [1.05 to 1.21]	European	(Strange et al. 2010)
	<i>RNF114</i>	rs1056198	Intron	$2.7 \times 10^{-6}$	1.2 [1.11 to 1.30]	European	(Tsoi et al. 2012)
22q11.21	<i>ZNF313</i>	rs495337	Cds-synon	$1.5 \times 10^{-14}$	1.16 [NR]	European	(Tsoi et al. 2012)
	<i>SDC4</i>	rs1008953	Intergenic	$1.7 \times 10^{-8}$	1.25 [1.12 to 1.39]	European	(Capon et al. 2008)
	<i>UBE2L3</i>	rs4821124	Intron	$1.7 \times 10^{-7}$	1.14 [NR]	European	(Stuart et al. 2010)
				$3.8 \times 10^{-8}$	1.13 [NR]	European	(Tsoi et al. 2012)

NR, not reported; UTR, untranslated region; ncRNA, noncoding RNA; nearGene-5/3, a SNP close to the 5' or 3' end of a gene. Intergenic: a stretch of sequences located between genes.

**Table 2 The algorithms of psoriasis GWAS**

Chromosomal	Reported gene(s)	SNP	Algorithms	Ref.
1q21.3	<i>LCE3B, LCE3D</i>	rs6677595	PLINK, minimac, IMPUTE2, PCA	(Tsoi et al. 2012)
	<i>LCE3D, LCE3A</i>	rs4085613	Plink 1.02, PCA, Cochran-Armitage trend test, Cochran-Mantel-Haenszel stratification analysis	(Zhang et al. 2009)
	<i>LCE3D</i>	rs4112788	SNPTEST, R, IMPUTE2, PHASE, logistic regression	(Strange et al. 2010)
1p36.23	<i>SLC45A1, TNFRSF9</i>	rs11121129	PLINK, minimac, IMPUTE2, PCA	(Tsoi et al. 2012)
1p36.11	<i>RUNX3</i>	rs7536201		
	<i>IL28RA</i>	rs7552167		
		rs4649203	SNPTEST, R, IMPUTE2, PHASE, logistic regression	(Strange et al. 2010)
			PCA, PLINK 1.07, R, EIGENSTRAT, Cochran-Armitage trend test	(Cheng et al. 2013)
1p31.3	<i>IL23R</i>	rs2201841	X <sup>2</sup> statistic, logistic regression, MACH	(Nair et al. 2009)
		rs9988642	PLINK, minimac, IMPUTE2, PCA	(Tsoi et al. 2012)
		rs11209026	SNPTEST, R, IMPUTE2, PHASE, logistic regression	(Strange et al. 2010)
2q24.3	<i>IFIH1</i>	rs17716942	SNPTEST, R, IMPUTE2, PHASE, logistic regression	(Strange et al. 2010)
2p16.1	<i>FLJ16341, REL</i>	rs62149416	PLINK, minimac, IMPUTE2, PCA	(Tsoi et al. 2012)
	<i>REL</i>	rs702873	SNPTEST, R, IMPUTE2, PHASE, logistic regression	(Strange et al. 2010)
	<i>NR</i>	rs842636	MACH version 1.0, Meta-analysis	(Stuart et al. 2010)
2p15	<i>B3GNT2</i>	rs10865331	PLINK, minimac, IMPUTE2, PCA	(Tsoi et al. 2012)
5q33.3	<i>PTTG1</i>	rs2431697	R, PCA, Cochran-Armitage trend test, Heterogeneity tests	(Sun et al. 2010)
	<i>IL12B</i>	rs12188300	PLINK, minimac, IMPUTE2, PCA	(Tsoi et al. 2012)
		rs2546890	MACH v.1.0.16, MACH2DAT, gPLINK v2.049, CopyCaller v1.0, METAL	(Ellinghaus et al. 2010)
		rs3213094	SNPTEST, R, IMPUTE2, PHASE, logistic regression	(Strange et al. 2010)
		rs2082412	X <sup>2</sup> statistic, logistic regression, MACH	(Nair et al. 2009)
		rs3213094	Plink 1.02, PCA, Cochran-Armitage trend test, Cochran-Mantel-Haenszel stratification analysis	(Zhang et al. 2009)
5q33.1	<i>TNIP1/ANXA6</i>	rs3762999	R, PCA, Cochran-Armitage trend test, Heterogeneity tests	(Sun et al. 2010)
		rs999556		
	<i>TNIP1</i>	rs17728338	X <sup>2</sup> statistic, logistic regression, MACH	(Nair et al. 2009)
		rs2233278	PLINK, minimac, IMPUTE2, PCA	(Tsoi et al. 2012)
5q15	<i>IL13, IL4</i>	rs1295685	PLINK, minimac, IMPUTE2, PCA	(Tsoi et al. 2012)
	<i>IL13</i>	rs20541	X <sup>2</sup> statistic, logistic regression, MACH	(Nair et al. 2009)
	<i>ERAP1</i>	rs27432	PLINK, minimac, IMPUTE2, PCA	(Tsoi et al. 2012)
5q15		rs27524	SNPTEST, R, IMPUTE2, PHASE, logistic regression	(Strange et al. 2010)
		rs151823	R, PCA, Cochran-Armitage trend test, Heterogeneity tests	(Sun et al. 2010)
5q15	<i>LNPEP</i>	rs2303138	PCA, PLINK 1.07, R, EIGENSTRAT, Cochran-Armitage trend	(Cheng et al. 2013)
6q25.4	<i>EXOC2, IRF4</i>	rs9504361	PLINK, minimac, IMPUTE2, PCA	(Tsoi et al. 2012)

**Table 2 The algorithms of psoriasis GWAS (Continued)**

6q25.3	<i>TAGAP</i>	rs2451258		
6q23.3	<i>TNFAIP3</i>	rs582757	PLINK, minimac, IMPUTE2, PCA	(Tsoi et al. 2012)
		rs610604	X <sup>2</sup> statistic, logistic regression , MACH	(Nair et al. 2009)
6q21	<i>TRAF3IP2</i>	rs33980500	PLINK, minimac, IMPUTE2, PCA	(Tsoi et al. 2012)
		rs458017	SNPTEST, R, IMPUTE2, PHASE, logistic regression	(Strange et al. 2010)
		rs13196377	birdseed-v2 algorithm, MACH1, X <sup>2</sup> test, Cochran-Mantel-Haenszel tests, PHASE	(Huffmeier et al. 2010)
		rs13190932		
		rs13210247		
		rs33980500	MACH v.1.0.16, MACH2DAT, gPLINK v2.049, CopyCaller v1.0, METAL	(Ellinghaus et al. 2010)
		rs240993	SNPTEST, R, IMPUTE2, PHASE, logistic regression	(Strange et al. 2010)
6p21.33	<i>HLA-C</i>	rs1265181	Plink 1.02, PCA, Cochran-Armitage trend test, Cochran-Mantel-Haenszel stratification analysis	(Zhang et al. 2009)
		rs13191343	birdseed-v2 algorithm, MACH1, Chi-Square test, Cochran-Mantel-Haenszel tests, PHASE	(Huffmeier et al. 2010)
		rs12191877	MACH v.1.0.16, MACH2DAT, gPLINK v2.049, CopyCaller v1.0, METAL	(Ellinghaus et al. 2010)
		rs10484554	SNPTEST, R, IMPUTE2, PHASE, logistic regression	(Strange et al. 2010)
		rs12191877	X <sup>2</sup> statistic, logistic regression , MACH	(Nair et al. 2009)
		rs10484554	STRUCTURE, EIGENSTRAT, Cochran-Armitage Test, R, Haploview 3.2	(Liu et al. 2008)
		rs3134792	Haploview software, Fisher's exact test, PLINK, I <sup>2</sup> statistic	(Capon et al. 2008)
	<i>HLA-B, HLA-C</i>	rs4406273	PLINK, minimac, IMPUTE2, PCA	(Tsoi et al. 2012)
	<i>HCP5</i>	rs2395029	STRUCTURE, EIGENSTRAT, Cochran-Armitage Test, R, Haploview 3.2	(Liu et al. 2008)
7p14.1	<i>ELMO1</i>	rs2700987	PLINK, minimac, IMPUTE2, PCA	(Tsoi et al. 2012)
8p23.2	<i>CSMD1</i>	rs7007032	R, PCA, Cochran-Armitage trend test, Heterogeneity tests	(Sun et al. 2010)
		rs10088247		
9q34.13	<i>TSC1</i>	rs1076160	X <sup>2</sup> statistic, logistic regression , MACH	(Nair et al. 2009)
9q31.2	<i>KLF4</i>	rs10979182	PLINK, minimac, IMPUTE2, PCA	(Tsoi et al. 2012)
9p21.1	<i>DDX58</i>	rs11795343		
10q22.3	<i>ZMIZ1</i>	rs1250546		
11q24.3	<i>ETS1</i>	rs3802826		
	<i>ZC3H12C</i>	rs4561177		
11q13.1	<i>RPS6KA4, PRDX5</i>	rs645078		
12q13.3	<i>STAT2, IL23A</i>	rs2066819	PLINK, minimac, IMPUTE2, PCA	(Tsoi et al. 2012)
	<i>IL23A, STAT2</i>	rs2066808	X <sup>2</sup> statistic, logistic regression , MACH	(Nair et al. 2009)
			SNPTEST, R, IMPUTE2, PHASE, logistic regression	(Strange et al. 2010)
12q13.2	<i>RPS26</i>	rs12580100	Imputation(MACH software version 1.0), Meta-analysis	(Stuart et al. 2010)
13q14.11	<i>COG6</i>	rs7993214	STRUCTURE, EIGENSTRAT, Cochran-Armitage Test, R, Haploview 3.2	(Liu et al. 2008)
	<i>GJB2</i>	rs3751385	R, PCA, Cochran-Armitage trend test, Heterogeneity tests	(Sun et al. 2010)

**Table 2 The algorithms of psoriasis GWAS (Continued)**

14q13.2	<i>NFKBIA, PSMA6</i>	rs12586317	Imputation(MACH software version 1.0), Meta-analysis	(Stuart et al. 2010)
	<i>NFKBIA</i>	rs8016947	SNPTEST, R, IMPUTE2, PHASE, logistic regression	(Strange et al. 2010)
			Cochran Armitage trend test, Cochran Mantel Haenszel stratification analysis, PLINK 1.07, R 15.1	(Li et al. 2013)
16p13.13	<i>PRM3, SOCS1</i>	rs367569	PLINK, minimac, IMPUTE2, PCA	(Tsoi et al. 2012)
16p11.2	<i>PRSS53, FBXL19</i>	rs12445568		
	<i>FBXL19,POL3S</i>	rs10782001	Imputation(MACH software version 1.0), Meta-analysis	(Stuart et al. 2010)
17q25.3	<i>CARD14</i>	rs11652075	PLINK, minimac, IMPUTE2, PCA	(Tsoi et al. 2012)
17q21.2	<i>PTRF, STAT3, STAT5A/B</i>	rs963986		
17q11.2	<i>NOS2</i>	rs28998802		
		rs4795067	Imputation(MACH software version 1.0), Meta-analysis	(Stuart et al. 2010)
	<i>NR</i>	rs1975974		
18q22.1	<i>SERPINB8</i>	rs514315	R, PCA, Cochran-Armitage trend test, Heterogeneity tests	(Sun et al. 2010)
18q21.2	<i>POL1, STARD6, MBD2</i>	rs545979	PLINK, minimac, IMPUTE2, PCA	(Tsoi et al. 2012)
19q13.41	<i>ZNF816A</i>	rs9304742	R, PCA, Cochran-Armitage trend test, Heterogeneity tests	(Sun et al. 2010)
19p13.2	<i>ILF3,CARM1</i>	rs892085	PLINK, minimac, IMPUTE2, PCA	(Tsoi et al. 2012)
	<i>TYK2</i>	rs34536443		
		rs12720356	SNPTEST, R, IMPUTE2, PHASE, logistic regression	(Strange et al. 2010)
		rs280519		
20q13.13	<i>ZNF313</i>	rs2235617		
	<i>RNF114</i>	rs1056198	PLINK, minimac, IMPUTE2, PCA	(Tsoi et al. 2012)
	<i>ZNF313</i>	rs495337	Haploview software, Fisher's exact test, PLINK, $I^2$ statistic	(Capon et al. 2008)
20q13.12	<i>SDC4</i>	rs1008953	Imputation(MACH software version 1.0), Meta-analysis	(Stuart et al. 2010)
22q11.21	<i>UBE2L3</i>	rs4821124	PLINK, minimac, IMPUTE2, PCA	(Tsoi et al. 2012)

PCA, principal-component analysis.

The GWAS of psoriasis patients have implicated several other susceptibility genes that are involved in various biological processes, including the IL-23/Th17 pathway (Ellinghaus et al. 2010; Huffmeier et al. 2010; Nair et al. 2009; Strange et al. 2010), NF- $\kappa$ B signaling (Nair et al. 2009; Strange et al. 2010; Stuart et al. 2010), epidermal cell differentiation (de Cid et al. 2009; Sun et al. 2010; Zhang et al. 2009), MHC class I processing (Strange et al. 2010; Sun et al. 2010), the ubiquitin pathway (Capon et al. 2008; Sun et al. 2010), and Th2-type response (Nair et al. 2009) as well as genes with yet unknown functions. As mentioned above, the functional role of IL-23-induced and Th17 cell-mediated chronic inflammation is highlighted in the immune-pathogenesis of psoriasis. In GWAS findings of both European and Chinese populations, different SNP alleles associated with psoriasis in and upstream of the *IL12B* gene and the *IL23R* gene have been identified, confirming the role of the IL-23/Th17 axis in psoriasis pathogenesis (Cargill et al. 2007; Nair et al. 2009; Zhang et al. 2009). *IL12B* (encoding the p40

subunit of IL-23 and IL-12) and *IL23A* (encoding the p19 subunit of IL-23) are heterodimerize to form IL-23. The IL-23/Th17 pathway signaling could promote cellular immune responses by strengthening of a subset of IL-17-expressing T cells (Bettelli et al. 2007) or dysregulation of expression ultimately resulting in psoriasis.

Several mediators of the NF- $\kappa$ B signaling pathways are linked to psoriasis (Goldminz et al. 2013). As revealed by GWAS, *TNFAIP3* (TNF- $\alpha$ -induced protein 3) and *TNIP1* (TNFAIP3-interacting protein 1), the gene products of which modulate this pathway show a strong association with the disease (Elder 2009; Nair et al. 2009). Genetic variants in the *TRAF3IP2* (TRAF3-interacting protein 2), which encodes a protein involved in IL-17 signaling, are implicated in psoriasis susceptibility (Ellinghaus et al. 2010; Huffmeier et al. 2010). *TRAF3IP2* interacts with tumor necrosis factor receptor-associated factor (TRAF) proteins and either I-B kinase or mitogen-activated protein kinase to activate either NF- $\kappa$ B or Jun kinase (Ellinghaus et al. 2010). Encoding endoplasmic reticulum aminopeptidase 1 (*ERAP1*), located in 5q15 associated region, which encodes an amino peptidase regulatory factor for the quality of peptides bound to MHC class I molecules, is implicated in psoriasis in both European and Chinese populations (Strange et al. 2010; Sun et al. 2010). Compelling evidence shows that it exits the interaction between the *HLA-C* and *ERAP1* loci in the psoriasis pathogenesis process. *ERAP1* variants could influence psoriasis susceptibility in individuals who carry the *HLA-C* risk allele (Strange et al. 2010). Variants of the gene encoding zinc-finger protein 313 (*ZNF313*) are also associated with psoriasis as well (Capon et al. 2008). *ZNF313* has a similar role of as the ubiquitin ligase of *TRAC-1* to regulate T cell activation. The present data also provide evidences that skin barrier function plays a role in psoriasis susceptibility. A deletion polymorphism of two genes (*LCE3C* and *LCE3B*) is associated with psoriasis in different populations (de Cid et al. 2009; Zhang et al. 2009). The *LCE* genes encode the stratum corneum proteins of the cornified envelope, which is important in epidermal terminal differentiation (Mischke et al. 1996). Genetic susceptibility variant(s) within the *LCE* genes may influence the development of psoriasis by interrupting the terminal differentiation of keratinocytes. Collectively, the genetic determinants could lead to dysregulation of innate and adaptive immunity and to epidermal barrier dysfunction in disease process.

### Common genetic factors in autoimmune or inflammatory diseases

To evaluate the relationship between psoriasis and autoimmune disease, the findings of one retrospective study suggest that psoriasis patients are more likely to be diagnosed with an autoimmune disease than individuals without psoriasis (Wu et al. 2012). Common autoimmune or inflammatory (immune-mediated) diseases, such as RA, CD, MS, celiac disease (CeD), inflammatory bowel disease (IBD), ankylosing spondylitis (AS), and systemic lupus erythematosus (SLE), are highly prevalent in psoriasis patients. Psoriasis and psoriatic arthritis (PsA) are interrelated disorders that share pathophysiological mechanisms. The occurrence of psoriasis in conjunction with chronic inflammatory arthritis is range from 10% to 30% of individuals with the disease.

Many confirmed and nominally associated psoriasis susceptibility loci show a high level of overlap with the associated loci of other autoimmune diseases. This marked overlap of autoimmune disease susceptibility loci may occur when the same variants contribute to multiple diseases or when different variants in the same gene confer



susceptibility to various autoimmune diseases. Typically, psoriasis is concomitant with autoimmune and inflammatory diseases (Makredes et al. 2009), sharing many susceptibility genes between them (Table 3). Several associated genes are also implicated in other immune-mediated disorders, notably CD (Ellinghaus et al. 2012), offering insights into the postulated shared pathogenesis of CD and PS. In addition to psoriasis, *IL23R* is associated with IBD, PsA, and MS (Duerr et al. 2006; Begovich et al. 2007; Liu et al. 2008), highlighting the functional role of the IL-23/Th17 axis in immune-mediated inflammatory and autoimmune processes. Furthermore, many genes involved in the NF- $\kappa$ B pathway, such as *TNFAIP3* and *NFKB1A*, are also linked to risk for other autoimmune diseases (Fung et al. 2009; Han et al. 2009; Bowes et al. 2010; Li et al. 2013). Although *HLA-C* remains the strongest susceptibility candidate gene in psoriasis, evidences for an interaction between *HLA-C* and other autoimmune diseases have been confirmed by GWAS (Raychaudhuri et al. 2012). These and other regions of genetic association shared with autoimmune diseases indicate that psoriasis may have similar immune mechanism and pathogenic pathways. However, common susceptibility genes among different phenotypes suggest that genetic variation may influence the entire pathways to increase the risk for multiple diseases.

### Next-generation sequencing

Our understanding of the genetic basis of psoriasis has been rapidly advanced by GWAS approach. More than 40 robust susceptibility loci have been identified and confirmed to be associated with psoriasis using this technique. However, most of the

**Table 3 Susceptibility genes in risk loci shared by autoimmune or inflammatory diseases**

Region	Reported gene (s)	Biological annotations	Autoimmune and inflammatory diseases overlap
1p31.3	<i>IL23R</i>	IL-23/Th17 axis	PsV, AS, BD, CD, LE, UC
1p36.11	<i>RUNX3</i>	CD8+ T lymphocyte differentiation	PsV, CD, AS, CeD
2q24.2	<i>IFIH1</i>	Interferon signaling pathway	PsV, T1D, vitiligo
2p16.1	<i>REL</i>	Rel/NF- $\kappa$ B family	PsV, PA, CD, RA, CeD, IBD
5q33.3	<i>IL12B</i>	Th1 cell differentiation	PsV, CD, IBD, MS, PA, UC,
5q33.1	<i>TNIP1</i>	NF- $\kappa$ B pathway	PsV, IBD, SS, SLE, myasthenia gravis
5q31.1	<i>IL13</i>	Th2 cell differentiation	PsV, IBD, asthma, AD
5q15	<i>ERAP1</i>	MHC class I processing	PsV, AS, BD
6q23.3	<i>TNFAIP3</i>	NF- $\kappa$ B pathway	PsV, CeD, SLE, IBD, RA
6q21	<i>TRAF3IP2</i>	NF- $\kappa$ B pathway; IL-23/Th17 axis	PsV, IBD, PA
6p21.33	<i>HLA-C</i>	MHC class I processing	PsV, CD, PA, CRD, SJS-TEN, vitiligo
10q22.3	<i>ZMIZ1</i>	Inhibitor of activated STAT	PsV, MS, CD, vitiligo, CeD, IBD,
11q24.3	<i>ETS1</i>	Regulation of Th17 and B cells	PsV, SLE, CD, RA
16p13.13	<i>SOC3</i>	IL-7RA/IL-7 pathway	PsV, MS, T1D
19p13.2	<i>TYK2</i>	IL-23/Th17 signaling	PsV, MS, T1D, CD
22q11.21	<i>UBE2L3</i>	Ubiquitin-conjugating enzyme	PsV, SLE, IBD, CeD, RA

(Using NHGR1 GWAS catalog data, <http://www.genome.gov/gwastudies/>). PsV, psoriasis vulgaris; PsA, psoriatic arthritis; AD, atopic dermatitis; IBD, inflammatory bowel disease; AS, ankylosing spondylitis; BD, Behcet's disease; CD, Crohn's disease; CeD, celiac disease; LE, leprosy; MS, multiple sclerosis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SS, systemic sclerosis; T1D, type 1 diabetes; UC, ulcerative colitis; SJS-TEN, Stevens-Johnson syndrome and toxic epidermal necrolysis.

identified risk variants are expected to be tagged as SNPs, and the functional coding variants of these susceptibility genes, particularly those that are of low frequency and rare, are largely refractory to the interrogation by GWAS. Therefore, such variants have not been systematically investigated. With the development of technologies for next-generation sequencing (NGS) technologies, such as exome sequencing analysis, the systematic investigation of coding variants is possible. Recently, a large-scale sequencing analysis of functional coding variants was performed to investigate the contribution of functional coding variants to the genetic susceptibility of psoriasis in a Han Chinese population, identifying seven common and low-frequency nonsynonymous variants within known psoriasis susceptibility genes, including *IL23R*, *GJB2*, *LCE3D*, *ERAP1*, *CARD14*, and *ZNF816A*, that are associated with psoriasis risk (Tang et al. 2013).

## Conclusions

The pathogenesis of psoriasis involves a complicated interaction between genetic and immunological and environmental components. During recent years, there have been great advances and tremendous achievements in immunity and genetic research on psoriasis that have contributed to the understanding of the mechanism of psoriasis. It is clear that Th1, Th17, and Th22 cells, which interact with each other, mediate the immunity response in disease development. Recent GWAS have identified a variety of genetic components involving both the immune system and the epidermis that affect psoriasis pathogenesis. Several genetic factors and pathways shared with autoimmune and inflammatory (immune-mediated) diseases highlight a common mechanism in different diseases. However, a substantial proportion of the involved genetic factors have yet to be identified, and it is difficult to clarify how these genetic factors and pathways intersect and contribute to inflammation, proliferation, and altered differentiation in psoriasis. Fine mapping and resequencing efforts, together with extensive functional studies, are required to detect all potential causal variants for the susceptibility to psoriasis. Recent advances in next-generation sequencing technologies will enable the increased understanding of the pathogenetic mechanisms and will position a number of confirmed genes or pathways as potential targets for future therapeutic intervention.

## Competing interests

The authors declare that they have no competing interests.

## Authors' contributions

XJZ conceived of the review and participated in its design and coordination. LDS designed the review, drafted the manuscript, and gave the final approval of the version to be published. Both authors read and approved the final manuscript.

## Authors' information

LDS M.D. Ph.D is a Professor of Dermatology, Assistant Director, Key Lab of Dermatology, Ministry of Education, Committee Member of Youth Commission of Genetics of China, Committee Member of Human and Medical Genetics of Genetics Society of China, and Director of Research Department at the First Affiliated Hospital of Anhui Medical University.

XJZ M.D. Ph.D is a Professor of Dermatology, Director of Institute of Dermatology, Anhui Medical University, Director of Key Lab of Dermatology, Ministry of Education, President of Chinese Society of Dermatology, Board of Director, International League of Dermatological Societies, President of Asian Dermatological Association, Associate editor, Journal of Investigative Dermatology, Editorial Advisory Board Member, British Journal of Dermatology, Editorial Board Member, Journal of Dermatological Science, Editorial Board Member, and International Journal of Dermatology.

## Acknowledgements

This work was supported by the National Science Fund for Excellent Young Scholars (81222022) and the Outstanding Talents of Organization Department of the CPC (Communist Party of China) Central Committee program.

Received: 19 July 2014 Accepted: 25 October 2014

Published online: 31 December 2014

## References

- Albanesi C, Scarponi C, Giustizieri ML, Girolomoni G (2005) Keratinocytes in inflammatory skin diseases. *Curr Drug Targets Inflamm Allergy* 4(3):329–334
- Arthur JS, Darragh J (2006) Signaling downstream of p38 in psoriasis. *J Invest Dermatol* 126(8):1689–1691, doi:10.1038/sj.jid.5700280
- Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG (1999) The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. *J Invest Dermatol* 113(5):752–759, doi:10.1046/j.1523-1747.1999.00749.x
- Begovich AB, Chang M, Caillier SJ, Lew D, Catanese JJ, Wang J, Hauser SL, Oksenberg JR (2007) The autoimmune disease-associated IL12B and IL23R polymorphisms in multiple sclerosis. *Hum Immunol* 68(11):934–937, doi:10.1016/j.humimm.2007.09.005
- Bettelli E, Oukka M, Kuchroo VK (2007) T(H)-17 cells in the circle of immunity and autoimmunity. *Nat Immunol* 8(4):345–350, doi:10.1038/ni0407-345
- Bhalerao J, Bowcock AM (1998) The genetics of psoriasis: a complex disorder of the skin and immune system. *Hum Mol Genet* 7(10):1537–1545
- Boehncke WH, Schon MP (2007) Animal models of psoriasis. *Clin Dermatol* 25(6):596–605, doi:10.1016/j.clindermatol.2007.08.014
- Boniface K, Guignouard E, Pedretti N, Garcia M, Delwail A, Bernard FX, Nau F, Guillet G, Dagregorio G, Yssel H, Lecron JC, Morel F (2007) A role for T cell-derived interleukin 22 in psoriatic skin inflammation. *Clin Exp Immunol* 150(3):407–415, doi:10.1111/j.1365-2249.2007.03511.x
- Bowcock AM, Krueger JG (2005) Getting under the skin: the immunogenetics of psoriasis. *Nat Rev Immunol* 5(9):699–711, doi:10.1038/nri1689
- Bowes J, Lawrence R, Eyre S, Panoutsopoulou K, Orozco G, Elliott KS, Ke X, Morris AP, Thomson W, Worthington J, Barton A, Zeggini E (2010) Rare variation at the TNFAIP3 locus and susceptibility to rheumatoid arthritis. *Hum Genet* 128(6):627–633, doi:10.1007/s00439-010-0889-1
- Cai Y, Fleming C, Yan J (2012) New insights of T cells in the pathogenesis of psoriasis. *Cell Mol Immunol* 9(4):302–309, doi:10.1038/cmi.2012.15
- Capon F, Bijlmaars MJ, Wolf N, Quaranta M, Huffmeier U, Allen M, Timms K, Abkevich V, Gutin A, Smith R, Warren RB, Young HS, Worthington J, Burden AD, Griffiths CE, Hayday A, Nestle FO, Reis A, Lanchbury J, Barker JN, Trembath RC (2008) Identification of ZNF313/RNF114 as a novel psoriasis susceptibility gene. *Hum Mol Genet* 17(13):1938–1945, doi:10.1093/hmg/ddn091
- Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, Callis KP, Matsunami N, Ardlie KG, Civeello D, Catanese JJ, Leong DU, Panko JM, McAllister LB, Hansen CB, Papenfuss J, Prescott SM, White TJ, Leppert MF, Krueger GG, Begovich AB (2007) A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. *Am J Hum Genet* 80(2):273–290, doi:10.1086/511051
- Cheng H, Li Y, Zuo XB, Tang HY, Tang XF, Gao JP, Sheng YJ, Yin XY, Zhou FS, Zhang C, Chen G, Zhu J, Qian P, Liang B, Zheng XD, Li P, Ding YT, Cheng F, Luo J, Chang RX, Pan GB, Fan X, Wang ZX, Zhang AP, Liu JJ, Yang S, Sun LD, Zhang XJ (2013) Identification of a missense variant in LNPEP that confers psoriasis risk. *J Invest Dermatol*. doi:10.1038/jid.2013.317
- Chu CC, Di Meglio P, Nestle FO (2011) Harnessing dendritic cells in inflammatory skin diseases. *Semin Immunol* 23(1):28–41, doi:10.1016/j.smim.2011.01.006
- Clark RA, Kupper TS (2006) Misbehaving macrophages in the pathogenesis of psoriasis. *J Clin Invest* 116(8):2084–2087, doi:10.1172/jci29441
- Costa C, Incio J, Soares R (2007) Angiogenesis and chronic inflammation: cause or consequence? *Angiogenesis* 10(3):149–166, doi:10.1007/s10456-007-9074-0
- Coto E, Santos-Juanes J, Coto-Segura P, Alvarez V (2011) New psoriasis susceptibility genes: momentum for skin-barrier disruption. *J Invest Dermatol* 131(5):1003–1005, doi:10.1038/jid.2011.14
- Cumberbatch M, Singh M, Dearman RJ, Young HS, Kimber I, Griffiths CE (2006) Impaired Langerhans cell migration in psoriasis. *J Exp Med* 203(4):953–960, doi:10.1084/jem.20052367
- Davidson A, Diamond B (2001) Autoimmune diseases. *N Engl J Med* 345(5):340–350, doi:10.1056/nejm200108023450506
- de Cid R, Riveira-Munoz E, Zeeuwen PL, Robarge J, Liao W, Dannhauser EN, Giardina E, Stuart PE, Nair R, Helms C, Escaramis G, Ballana E, Martin-Ezquerro G, den Heijer M, Kamsteeg M, Joosten I, Eichler EE, Lazaro C, Pujol RM, Armengol L, Abecasis G, Elder JT, Novelli G, Armour JA, Kwok PY, Bowcock A, Schalkwijk J, Estivill X (2009) Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. *Nat Genet* 41(2):211–215, doi:10.1038/ng.313
- Di Cesare A, Di Meglio P, Nestle FO (2009) The IL-23/Th17 axis in the immunopathogenesis of psoriasis. *J Invest Dermatol* 129(6):1339–1350, doi:10.1038/jid.2009.59
- Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, Abraham C, Regueiro M, Griffiths A, Dassopoulos T, Bitton A, Yang H, Targan S, Datta LW, Kistner EO, Schumm LP, Lee AT, Gregersen PK, Barnada MM, Rotter JJ, Nicolae DL, Cho JH (2006) A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. *Science* 314(5804):1461–1463, doi:10.1126/science.1135245
- Elder JT (2006) PSORS1: linking genetics and immunology. *J Invest Dermatol* 126(6):1205–1206, doi:10.1038/sj.jid.5700357
- Elder JT (2009) Genome-wide association scan yields new insights into the immunopathogenesis of psoriasis. *Genes Immun* 10(3):201–209, doi:10.1038/gene.2009.11
- Ellinghaus E, Ellinghaus D, Stuart PE, Nair RP, Debrus S, Raelson JV, Belouchi M, Fournier H, Reinhard C, Ding J, Li Y, Tejasvi T, Gudjonsson J, Stoll SW, Voorhees JJ, Lambert S, Weidinger S, Eberlein B, Kunz M, Rahman P, Gladman DD, Gieger C, Wichmann HE, Karlsen TH, Mayr G, Albrecht M, Kabelitz D, Mrowietz U, Abecasis GR, Elder JT et al (2010)

- Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. *Nat Genet* 42(11):991–995, doi:10.1038/ng.689
- Ellinghaus D, Ellinghaus E, Nair RP, Stuart PE, Esko T, Metspalu A, Debrus S, Raelson JV, Tejasvi T, Belouchi M, West SL, Barker JN, Koks S, Kingo K, Balschun T, Palmieri O, Annese V, Gieger C, Wichmann HE, Kabesch M, Trembath RC, Mathew CG, Abecasis GR, Weidinger S, Nikolaus S, Schreiber S, Elder JT, Weichenthal M, Nothnagel M, Franke A (2012) Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. *Am J Hum Genet* 90(4):636–647, doi:10.1016/j.ajhg.2012.02.020
- Enlund F, Samuelsson L, Enerback C, Inerot A, Wahlstrom J, Yhr M, Torinsson A, Riley J, Swanbeck G, Martinsson T (1999) Psoriasis susceptibility locus in chromosome region 3q21 identified in patients from southwest Sweden. *Eur J Hum Genet* 7(7):783–790, doi:10.1038/sj.ejhg.5200365
- Ettehad P, Greaves MW, Wallach D, Aderka D, Camp RD (1994) Elevated tumour necrosis factor- $\alpha$  (TNF- $\alpha$ ) biological activity in psoriatic skin lesions. *Clin Exp Immunol* 96(1):146–151
- Feng BJ, Sun LD, Soltani-Arabshahi R, Bowcock AM, Nair RP, Stuart P, Elder JT, Schrod J, Begovich AB, Abecasis GR, Zhang XJ, Callis-Duffin KP, Krueger GG, Goldgar DE (2009) Multiple loci within the major histocompatibility complex confer risk of psoriasis. *PLoS Genet* 5(8):e1000606, doi:10.1371/journal.pgen.1000606
- Foerster J, Nolte I, Schweiger S, Ehler C, Bruinenberg M, Spaar K, van der Steege G, Mulder M, Kalscheuer V, Moser B, Kijas Z, Seeman P, Stander M, Sterry W, te Meerman G (2004) Evaluation of the IRF-2 gene as a candidate for PSORS3. *J Invest Dermatol* 122(1):61–64, doi:10.1046/j.0022-202X.2003.22104.x
- Friedrich M, Krammig S, Henze M, Docke WD, Sterry W, Asadullah K (2000) Flow cytometric characterization of lesional T cells in psoriasis: intracellular cytokine and surface antigen expression indicates an activated, memory/effector type 1 immunophenotype. *Arch Dermatol Res* 292(10):519–521
- Fujita H, Nogales KE, Kikuchi T, Gonzalez J, Carucci JA, Krueger JG (2009) Human Langerhans cells induce distinct IL-22-producing CD4<sup>+</sup> T cells lacking IL-17 production. *Proc Natl Acad Sci U S A* 106(51):21795–21800, doi:10.1073/pnas.0911472106
- Funding AT, Johansen C, Kragballe K, Otkjaer K, Jensen UB, Madsen MW, Fjording MS, Finnemann J, Skak-Nielsen T, Paludan SR, Iversen L (2006) Mitogen- and stress-activated protein kinase 1 is activated in lesional psoriatic epidermis and regulates the expression of pro-inflammatory cytokines. *J Invest Dermatol* 126(8):1784–1791, doi:10.1038/sj.jid.5700252
- Funding AT, Johansen C, Kragballe K, Iversen L (2007) Mitogen- and stress-activated protein kinase 2 and cyclic AMP response element binding protein are activated in lesional psoriatic epidermis. *J Invest Dermatol* 127(8):2012–2019, doi:10.1038/sj.jid.5700821
- Fung EY, Smyth DJ, Howson JM, Cooper JD, Walker NM, Stevens H, Wicker LS, Todd JA (2009) Analysis of 17 autoimmune disease-associated variants in type 1 diabetes identifies 6q23/TNFAIP3 as a susceptibility locus. *Genes Immun* 10(2):188–191, doi:10.1038/gene.2008.99
- Gaspari AA (2006) Innate and adaptive immunity and the pathophysiology of psoriasis. *J Am Acad Dermatol* 54(3 Suppl 2):S67–S80, doi:10.1016/j.jaad.2005.10.057
- Goldminz AM, Au SC, Kim N, Gottlieb AB, Lizzul PF (2013) NF- $\kappa$ B: an essential transcription factor in psoriasis. *J Dermatol Sci* 69(2):89–94, doi:10.1016/j.jdermsci.2012.11.002
- Griffiths CE, Barker JN (2007) Pathogenesis and clinical features of psoriasis. *Lancet* 370(9583):263–271, doi:10.1016/S0140-6736(07)61128-3
- Gudjonsson JE, Johnston A, Sigmundsdottir H, Valdimarsson H (2004) Immunopathogenic mechanisms in psoriasis. *Clin Exp Immunol* 135(1):1–8
- Gunther C, Carballido-Perrig N, Kaesler S, Carballido JM, Biedermann T (2012) CXCL16 and CXCR6 are upregulated in psoriasis and mediate cutaneous recruitment of human CD8<sup>+</sup> T cells. *J Invest Dermatol* 132(3 Pt 1):626–634, doi:10.1038/jid.2011.371
- Hald A, Andres RM, Salskov-Iversen ML, Kjellerup RB, Iversen L, Johansen C (2013) STAT1 expression and activation is increased in lesional psoriatic skin. *Br J Dermatol* 168(2):302–310, doi:10.1111/bjd.12049
- Han JW, Zheng HF, Cui Y, Sun LD, Ye DQ, Hu Z, Xu JH, Cai ZM, Huang W, Zhao GP, Xie HF, Fang H, Lu QJ, Li XP, Pan YF, Deng DQ, Zeng FQ, Ye ZZ, Zhang XY, Wang QW, Hao F, Ma L, Zuo XB, Zhou FS, Du WH, Cheng YL, Yang JQ, Shen SK, Li J, Sheng YJ et al (2009) Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. *Nat Genet* 41(11):1234–1237, doi:10.1038/ng.472
- Harper EG, Guo C, Rizzo H, Lillis JV, Kurtz SE, Skorcheva I, Purdy D, Fitch E, Iordanov M, Blauvelt A (2009) Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. *J Invest Dermatol* 129(9):2175–2183, doi:10.1038/jid.2009.65
- Henseler T, Christophers E (1985) Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. *J Am Acad Dermatol* 13(3):450–456
- Huffmeier U, Lascorz J, Traupe H, Bohm B, Schurmeier-Horst F, Stander M, Kelsch R, Baumann C, Kuster W, Burkhardt H, Reis A (2005) Systematic linkage disequilibrium analysis of SLC12A8 at PSORS5 confirms a role in susceptibility to psoriasis vulgaris. *J Invest Dermatol* 125(5):906–912, doi:10.1111/j.0022-202X.2005.23847.x
- Huffmeier U, Lascorz J, Becker T, Schurmeier-Horst F, Magener A, Ekici AB, Ende S, Thiel CT, Thoma-Urszyski S, Mossner R, Reich K, Kurat W, Wienker TF, Traupe H, Reis A (2009) Characterisation of psoriasis susceptibility locus 6 (PSORS6) in patients with early onset psoriasis and evidence for interaction with PSORS1. *J Med Genet* 46(11):736–744, doi:10.1136/jmg.2008.065029
- Huffmeier U, Uebe S, Ekici AB, Bowes J, Giardina E, Korendowych E, Juneblad K, Apel M, McManus R, Ho P, Bruce IN, Ryan AW, Behrens F, Lascorz J, Bohm B, Traupe H, Lohmann J, Gieger C, Wichmann HE, Herold C, Steffens M, Klareskog L, Wienker TF, Fitzgerald O, Alenius GM, McHugh NJ, Novelli G, Burkhardt H, Barton A, Reis A (2010) Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. *Nat Genet* 42(11):996–999, doi:10.1038/ng.688
- Ibrahim G, Waxman R, Helliwell PS (2009) The prevalence of psoriatic arthritis in people with psoriasis. *Arthritis Rheum* 61(10):1373–1378, doi:10.1002/art.24608
- Jordan CT, Cao L, Roberson ED, Pierson KC, Yang CF, Joyce CE, Ryan C, Duan S, Helms CA, Liu Y, Chen Y, McBride AA, Hwu WL, Wu JY, Chen YT, Menter A, Goldbach-Mansky R, Lowes MA, Bowcock AM (2012) PSORS2 is due to mutations in CARD14. *Am J Hum Genet* 90(5):784–795, doi:10.1016/j.ajhg.2012.03.012

- Kaminska B, Swiatek-Machado K (2008) Targeting signaling pathways with small molecules to treat autoimmune disorders. *Expert Rev Clin Immunol* 4(1):93–112, doi:10.1586/1744666x.4.1.93
- Krueger JG (2002) The immunologic basis for the treatment of psoriasis with new biologic agents. *J Am Acad Dermatol* 46(1):1–23, quiz 23–26
- Lebwohl M (2003) Psoriasis. *Lancet* 361(9364):1197–1204, doi:10.1016/s0140-6736(03)12954-6
- Lee YA, Ruschendorf F, Windemuth C, Schmitt-Egenolf M, Stadelmann A, Nurnberg G, Stander M, Wienker TF, Reis A, Traupe H (2000) Genomewide scan in german families reveals evidence for a novel psoriasis-susceptibility locus on chromosome 19p13. *Am J Hum Genet* 67(4):1020–1024, doi:10.1086/303075
- Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, Chamian F, Dhodapkar M, Krueger JG (2004) Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. *J Exp Med* 199(1):125–130, doi:10.1084/jem.20030451
- Lew W, Bowcock AM, Krueger JG (2004) Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and Type 1 inflammatory gene expression. *Trends Immunol* 25(6):295–305, doi:10.1016/j.it.2004.03.006
- Li Y, Cheng H, Zuo XB, Sheng YJ, Zhou FS, Tang XF, Tang HY, Gao JP, Zhang Z, He SM, Lv YM, Zhu KJ, Hu DY, Liang B, Zhu J, Zheng XD, Sun LD, Yang S, Cui Y, Liu JJ, Zhang XJ (2013) Association analyses identifying two common susceptibility loci shared by psoriasis and systemic lupus erythematosus in the Chinese Han population. *J Med Genet*. doi:10.1136/jmedgenet-2013-101787
- Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, Fouser LA (2006) Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. *J Exp Med* 203(10):2271–2279, doi:10.1084/jem.20061308
- Liu Y, Krueger JG, Bowcock AM (2007) Psoriasis: genetic associations and immune system changes. *Genes Immun* 8(1):1–12, doi:10.1038/sj.gene.6364351
- Liu Y, Helms C, Liao W, Zaba LC, Duan S, Gardner J, Wise C, Miner A, Malloy MJ, Pullinger CR, Kane JP, Saccone S, Worthington J, Bruce I, Kwok PY, Menter A, Krueger J, Barton A, Saccone NL, Bowcock AM (2008) A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. *PLoS Genet* 4(3):e1000041, doi:10.1371/journal.pgen.1000041
- Lizzul PF, Aphale A, Malaviya R, Sun Y, Masud S, Dombrovskiy V, Gottlieb AB (2005) Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. *J Invest Dermatol* 124(6):1275–1283, doi:10.1111/j.0022-202X.2005.23735.x
- Lowes MA, Bowcock AM, Krueger JG (2007) Pathogenesis and therapy of psoriasis. *Nature* 445(7130):866–873, doi:10.1038/nature05663
- Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, Haider AS, Bowman EP, Krueger JG (2008) Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. *J Invest Dermatol* 128(5):1207–1211, doi:10.1038/sj.jid.5701213
- Lu X, Du J, Liang J, Zhu X, Yang Y, Xu J (2013) Transcriptional regulatory network for psoriasis. *J Dermatol* 40(1):48–53, doi:10.1111/1346-8138.12000
- Makredes M, Robinson D Jr, Bala M, Kimball AB (2009) The burden of autoimmune disease: a comparison of prevalence ratios in patients with psoriatic arthritis and psoriasis. *J Am Acad Dermatol* 61(3):405–410, doi:10.1016/j.jaad.2009.02.015
- Manolio TA, Brooks LD, Collins FS (2008) A HapMap harvest of insights into the genetics of common disease. *J Clin Invest* 118(5):1590–1605, doi:10.1172/jci34772
- Matthews D, Fry L, Powles A, Weber J, McCarthy M, Fisher E, Davies K, Williamson R (1996) Evidence that a locus for familial psoriasis maps to chromosome 4q. *Nat Genet* 14(2):231–233, doi:10.1038/ng1096-231
- Miossec P, Korn T, Kuchroo VK (2009) Interleukin-17 and type 17 helper T cells. *N Engl J Med* 361(9):888–898, doi:10.1056/NEJMr0707449
- Mischke D, Korge BP, Marenholz I, Volz A, Ziegler A (1996) Genes encoding structural proteins of epidermal cornification and S100 calcium-binding proteins form a gene complex (epidermal differentiation complex) on human chromosome 1q21. *J Invest Dermatol* 106(5):989–992
- Mueller W, Herrmann B (1979) Cyclosporin A for psoriasis. *N Engl J Med* 301(10):555, doi:10.1056/nejm197909063011016
- Nair RP, Henseler T, Jenisch S, Stuart P, Bichakjian CK, Lenk W, Westphal E, Guo SW, Christophers E, Voorhees JJ, Elder JT (1997) Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. *Hum Mol Genet* 6(8):1349–1356
- Nair RP, Stuart PE, Nistor I, Hiremagalore R, Chia NV, Jenisch S, Weichenthal M, Abecasis GR, Lim HW, Christophers E, Voorhees JJ, Elder JT (2006) Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. *Am J Hum Genet* 78(5):827–851, doi:10.1086/503821
- Nair RP, Duffin KC, Helms C, Ding J, Stuart PE, Goldgar D, Gudjonsson JE, Li Y, Tejasvi T, Feng BJ, Ruether A, Schreiber S, Weichenthal M, Gladman D, Rahman P, Schrod J, Prahalad S, Guthery SL, Fischer J, Liao W, Kwok PY, Menter A, Lathrop GM, Wise CA, Begovich AB, Voorhees JJ, Elder JT, Krueger GG, Bowcock AM, Abecasis GR (2009) Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. *Nat Genet* 41(2):199–204, doi:10.1038/ng.311
- Nakajima K (2012) Critical role of the interleukin-23/T-helper 17 cell axis in the pathogenesis of psoriasis. *J Dermatol* 39(3):219–224, doi:10.1111/j.1346-8138.2011.01458.x
- Nestle FO, Turka LA, Nickoloff BJ (1994) Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines. *J Clin Invest* 94(1):202–209, doi:10.1172/jci117308
- Nestle FO, Conrad C, Tun-Kyi A, Homey B, Gombert M, Boyman O, Burg G, Liu YJ, Gilliet M (2005) Plasmacytoid dendritic cells initiate psoriasis through interferon-alpha production. *J Exp Med* 202(1):135–143, doi:10.1084/jem.20050500
- Nestle FO, Kaplan DH, Barker J (2009) Psoriasis. *N Engl J Med* 361(5):496–509, doi:10.1056/NEJMr0804595
- Nickoloff BJ, Nestle FO (2004) Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. *J Clin Invest* 113(12):1664–1675, doi:10.1172/jci22147
- Nogales KE, Zaba LC, Guttman-Yassky E, Fuentes-Duculan J, Suarez-Farinas M, Cardinale I, Khatcherian A, Gonzalez J, Pierson KC, White TR, Pensabene C, Coats I, Novitskaya I, Lowes MA, Krueger JG (2008) Th17 cytokines interleukin



- (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. *Br J Dermatol* 159(5):1092–1102, doi:10.1111/j.1365-2133.2008.08769.x
- Perera GK, Di Meglio P, Nestle FO (2012) Psoriasis. *Annu Rev Pathol* 7:385–422, doi:10.1146/annurev-pathol-011811-132448
- Price AL, Zaitlen NA, Reich D, Patterson N (2010) New approaches to population stratification in genome-wide association studies. *Nat Rev Genet* 11(7):459–463, doi:10.1038/nrg2813
- Raychaudhuri S, Sandor C, Stahl EA, Freudenberg J, Lee HS, Jia X, Alfredsson L, Padyukov L, Klareskog L, Worthington J, Siminovitch KA, Bae SC, Plenge RM, Gregersen PK, de Bakker PI (2012) Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. *Nat Genet* 44(3):291–296, doi:10.1038/ng.1076
- Samuelsson L, Stiller C, Friberg C, Nilsson C, Inerot A, Wahlstrom J (2004) Association analysis of cystatin A and zinc finger protein 148, two genes located at the psoriasis susceptibility locus PSORS5. *J Invest Dermatol* 122(6):1399–1400, doi:10.1046/j.0022-202X.2004.12604.x
- Schlaak JF, Buslau M, Jochum W, Hermann E, Girdt M, Gallati H, Meyer zum Buschenfelde KH, Fleischer B (1994) T cells involved in psoriasis vulgaris belong to the Th1 subset. *J Invest Dermatol* 102(2):145–149
- Shi X, Jin L, Dang E, Chang T, Feng Z, Liu Y, Wang G (2011) IL-17A upregulates keratin 17 expression in keratinocytes through STAT1- and STAT3-dependent mechanisms. *J Invest Dermatol* 131(12):2401–2408, doi:10.1038/jid.2011.222
- Strange A, Capon F, Spencer CC, Knight J, Weale ME, Allen MH, Barton A, Band G, Bellenguez C, Bergboer JG, Blackwell JM, Bramon E, Bumpstead SJ, Casas JP, Cork MJ, Corvin A, Deloukas P, Dilthey A, Duncanson A, Edkins S, Estivill X, Fitzgerald O, Freeman C, Giardina E, Gray E, Hofer A, Huffmeier U, Hunt SE, Irvine AD, Jankowski J et al (2010) A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. *Nat Genet* 42(11):985–990, doi:10.1038/ng.694
- Stuart PE, Nair RP, Ellinghaus E, Ding J, Tejasvi T, Gudjonsson JE, Li Y, Weidinger S, Eberlein B, Gieger C, Wichmann HE, Kunz M, Ike R, Krueger GG, Bowcock AM, Mrowietz U, Lim HW, Voorhees JJ, Abecasis GR, Weichenthal M, Franke A, Rahman P, Gladman DD, Elder JT (2010) Genome-wide association analysis identifies three psoriasis susceptibility loci. *Nat Genet* 42(11):1000–1004, doi:10.1038/ng.693
- Sun LD, Cheng H, Wang ZX, Zhang AP, Wang PG, Xu JH, Zhu QX, Zhou HS, Ellinghaus E, Zhang FR, Pu XM, Yang XQ, Zhang JZ, Xu AE, Wu RN, Xu LM, Peng L, Helms CA, Ren YQ, Zhang C, Zhang SM, Nair RP, Wang HY, Lin GS, Stuart PE, Fan X, Chen G, Tejasvi T, Li P, Zhu J et al (2010) Association analyses identify six new psoriasis susceptibility loci in the Chinese population. *Nat Genet* 42(11):1005–1009, doi:10.1038/ng.690
- Tang A, Amagai M, Granger LG, Stanley JR, Udey MC (1993) Adhesion of epidermal Langerhans cells to keratinocytes mediated by E-cadherin. *Nature* 361(6407):82–85, doi:10.1038/361082a0
- Tang H, Jin X, Li Y, Jiang H, Tang X, Yang X, Cheng H, Qiu Y, Chen G, Mei J, Zhou F, Wu R, Zuo X, Zhang Y, Zheng X, Cai Q, Yin X, Quan C, Shao H, Cui Y, Tian F, Zhao X, Liu H, Xiao F, Xu F, Han J, Shi D, Zhang A, Zhou C, Li Q, et al. (2013) A large-scale screen for coding variants predisposing to psoriasis. *Nat Genet*. doi:10.1038/ng.2827
- Tobin AM, Kirby B (2005) TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. *BioDrugs* 19(1):47–57
- Trifari S, Kaplan CD, Tran EH, Crellin NK, Spits H (2009) Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. *Nat Immunol* 10(8):864–871, doi:10.1038/ni.1770
- Tsoi LC, Spain SL, Knight J, Ellinghaus E, Stuart PE, Capon F, Ding J, Li Y, Tejasvi T, Gudjonsson JE, Kang HM, Allen MH, McManus R, Novelli G, Samuelsson L, Schalkwijk J, Stahl M, Burden AD, Smith CH, Cork MJ, Estivill X, Bowcock AM, Krueger GG, Weger W, Worthington J, Tazi-Ahnini R, Nestle FO, Hayday A, Hoffmann P, Winkelmann J et al (2012) Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. *Nat Genet* 44(12):1341–1348, doi:10.1038/ng.2467
- Uyemura K, Yamamura M, Fivenson DF, Modlin RL, Nickoloff BJ (1993) The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. *J Invest Dermatol* 101(5):701–705
- Van Belle AB, de Heusch M, Lemaire MM, Hendrickx E, Warnier G, Dunussi-Joannopoulos K, Fouser LA, Renauld JC, Dumoutier L (2012) IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice. *J Immunol* 188(1):462–469, doi:10.4049/jimmunol.1102224
- Veal CD, Clough RL, Barber RC, Mason S, Tillman D, Ferry B, Jones AB, Ameen M, Balendran N, Powis SH, Burden AD, Barker JN, Trembath RC (2001) Identification of a novel psoriasis susceptibility locus at 1p and evidence of epistasis between PSORS1 and candidate loci. *J Med Genet* 38(1):7–13
- Veal CD, Capon F, Allen MH, Heath EK, Evans JC, Jones A, Patel S, Burden D, Tillman D, Barker JN, Trembath RC (2002) Family-based analysis using a dense single-nucleotide polymorphism-based map defines genetic variation at PSORS1, the major psoriasis-susceptibility locus. *Am J Hum Genet* 71(3):554–564, doi:10.1086/342289
- Vollmer S, Menssen A, Prinz JC (2001) Dominant lesional T cell receptor rearrangements persist in relapsing psoriasis but are absent from nonlesional skin: evidence for a stable antigen-specific pathogenic T cell response in psoriasis vulgaris. *J Invest Dermatol* 117(5):1296–1301, doi:10.1046/j.0022-202x.2001.01494.x
- Wang H, Peters T, Kess D, Sindrilaru A, Oreshkova T, Van Rooijen N, Stratis A, Renkl AC, Sunderkotter C, Wlaschek M, Haase I, Scharffetter-Kochanek K (2006) Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation. *J Clin Invest* 116(8):2105–2114, doi:10.1172/jci27180
- Wang H, Peters T, Sindrilaru A, Scharffetter-Kochanek K (2009a) Key role of macrophages in the pathogenesis of CD18 hypomorphic murine model of psoriasis. *J Invest Dermatol* 129(5):1100–1114, doi:10.1038/jid.2009.43
- Wang H, Syrovets T, Kess D, Buchele B, Hainzl H, Lunov O, Weiss JM, Scharffetter-Kochanek K, Simmet T (2009b) Targeting NF-kappa B with a natural triterpenoid alleviates skin inflammation in a mouse model of psoriasis. *J Immunol* 183(7):4755–4763, doi:10.4049/jimmunol.0900521
- Wu JJ, Nguyen TU, Poon KY, Herrinton LJ (2012) The association of psoriasis with autoimmune diseases. *J Am Acad Dermatol* 67(5):924–930, doi:10.1016/j.jaad.2012.04.039
- Yan KL, Huang W, Zhang XJ, Yang S, Chen YM, Xiao FL, Fan X, Gao M, Cui Y, Zhang GL, Sun LD, Wang PG, Chen JJ, Li W, Chen ZH, Wang ZM, Wang DZ, Zhang KY, Liu JJ (2007) Follow-up analysis of PSORS9 in 151 Chinese families confirmed the linkage to 4q31-32 and refined the evidence to the families of early-onset psoriasis. *J Invest Dermatol* 127(2):312–318, doi:10.1038/sj.jid.5700506



- Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, Abello MV, Novitskaya I, Pierson KC, Gonzalez J, Krueger JG, Lowes MA (2009) Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. *J Invest Dermatol* 129(1):79–88, doi:10.1038/jid.2008.194
- Zhang XJ, Zhang AP, Yang S, Gao M, Wei SC, He PP, Wang HY, Song YX, Cui Y, Chen JJ (2003) Association of HLA class I alleles with psoriasis vulgaris in southeastern Chinese Hans. *J Dermatol Sci* 33(1):1–6
- Zhang XJ, Yan KL, Wang ZM, Yang S, Zhang GL, Fan X, Xiao FL, Gao M, Cui Y, Wang PG, Sun LD, Zhang KY, Wang B, Wang DZ, Xu SJ, Huang W, Liu JJ (2007) Polymorphisms in interleukin-15 gene on chromosome 4q31.2 are associated with psoriasis vulgaris in Chinese population. *J Invest Dermatol* 127(11):2544–2551, doi:10.1038/sj.jid.5700896
- Zhang XJ, Huang W, Yang S, Sun LD, Zhang FY, Zhu QX, Zhang FR, Zhang C, Du WH, Pu XM, Li H, Xiao FL, Wang ZX, Cui Y, Hao F, Zheng J, Yang XQ, Cheng H, He CD, Liu XM, Xu LM, Zheng HF, Zhang SM, Zhang JZ, Wang HY, Cheng YL, Ji BH, Fang QY, Li YZ, Zhou FS et al (2009) Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. *Nat Genet* 41(2):205–210, doi:10.1038/ng.310
- Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J, Ouyang W (2007) Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. *Nature* 445(7128):648–651, doi:10.1038/nature05505

doi:10.1186/s40535-014-0003-1

**Cite this article as:** Sun and Zhang: The immunological and genetic aspects in psoriasis. *Applied Informatics* 2014 1:3.

**Submit your manuscript to a SpringerOpen<sup>®</sup> journal and benefit from:**

- Convenient online submission
- Rigorous peer review
- Immediate publication on acceptance
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

---

Submit your next manuscript at ► [springeropen.com](http://springeropen.com)